Bayer to be cell therapy player through $225m stem cell JV

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Olique
Image: iStock/Olique

Related tags: Stem cell

Bayer has launched itself into the cell therapy space through a $225m joint venture focused on developing induced pluripotent stem cells (iPSC).

The German biopharma has teamed up with healthcare investment firm Versant Ventures to form BlueRock Therapeutics, a company looking to develop stem cell based therapies for – initially - cardiovascular diseases and neurodegenerative disorders.

According to Bayer spokeswoman Katharina Jansen, this is Bayer’s first venture in the field of cell based therapies and the firm’s foundations will be based on iPSC technology platform invented by Nobel Prize winner Dr. Shinya Yamanaka of Kyoto University.

“The Nobel prize was rewarded for the iPSC technology in 2012, it was invented in 2006,”​ Jansen told us. “In the timeframes of bringing scientific breakthroughs into application this is not a very long time.”

The technology - licensed to BlueRock from iPS Academia in Japan – is based on the harvesting of skin cells, blocking off certain genome segments, and reprogramming the blocked-off segments to produce an iPSC which can use the entire genome. These cells are then exposed to specific growth factors – nerve cells, liver cells, heart muscle cells, etc – to determine the type of cell culture into which they will develop.

Bayer and Versant have committed $225m (€212m) to the venture which will have R&D operations in Toronto, Canada and in New York and Boston, US.

As for manufacturing, BlueRock will work with CCRM (Centre for Commercialisation of Regenerative medicine) which has cGMP cell therapy production facility in Toronto offering both clinical and commercial scale.

“iPSC technology has the potential to successfully tackle some of the most challenging diseases on this planet,”​ Axel Bouchon, head of the Bayer Lifescience Center (BLSC), said in a statement. An initial BlueRock programme will look at regenerating heart muscle in patients who have had a heart attack.

“We are fully aware that this will take time and there are many obstacles to overcome. But by combining the best minds around the globe and providing bold resources we believe we can achieve this ultimate goal of curing such diseases.”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars